
News|Articles|April 28, 2025
What 5 Managed Care Trends Experts Say You’re Not Watching Closely Enough
Author(s)Briana Contreras
Managed Healthcare Executive asked several experts in healthcare and managed care to share the trends they think the industry is overlooking. From rising costs and data challenges to shifts in how care is delivered, these are the issues that could have a major impact — and deserve a closer look.
Advertisement
Advertisement
Lately in managed care, certain trends have been in the spotlight more than others—including the growth of GLP-1 drugs, the rise of AI tools and the rules under the Inflation Reduction Act (IRA)—which are reshaping the Medicare Part D benefit by capping out-of-pocket costs, limiting insulin copays and enabling Medicare to negotiate drug prices.
Related to this article

Takeda’s Orzeyful, the first orexin agonist for narcolepsy type 1, is now available in the U.S. at a whole acquisition list price of $16,500 per 60-tablet bottle.

The FDA approved Cosentyx for polymyalgia rheumatica after 40.5% of trial patients reached sustained remission at week 52 vs. 20.5% on placebo.

SBE303, a Nectin-4 ADC for previously treated bladder cancer, is in phase 1 as the company advances SB27, its proposed Keytruda biosimilar.

NeosRx CEO Jeff Dunn, Pharm.D., MBA, explains how 340B claims can disadvantage PBMs because of loss of rebates..

A CMS rule moving insulin pumps and CGMs into Medicare bidding by 2028 has drawn a coalition letter and a Senate bill seeking delay.

Patients facing higher out-of-pocket costs predicted procedures would hurt more than procedures with no copay, according to the results of a recent Carnegie Mellon study.

A mouse study found that how much antigen sits on a vaccine’s surface, not just its size or shape, drives the T-cell response.
Advertisement
Advertisement
